Publication: First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012
1
Issued Date
2018-05-01
Resource Type
ISSN
10968652
03618609
03618609
Other identifier(s)
2-s2.0-85044243092
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
American Journal of Hematology. Vol.93, No.5 (2018), 643-648
Suggested Citation
Andrea Bacigalupo, Rosi Oneto, Hubert Schrezenmeier, Britta Hochsmann, Carlo Dufour, Seiji Kojima, Xiaofan Zhu, Xiaojuan Chen, Surapol Issaragrisil, Suporn Chuncharunee, Dae Chul Jeong, Sabrina Giammarco, Maria Teresa Van Lint, Yizhou Zheng, Carlos Vallejo First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012. American Journal of Hematology. Vol.93, No.5 (2018), 643-648. doi:10.1002/ajh.25081 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/46738
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012
Other Contributor(s)
Ospedale Policlinico San Martino
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore
Chinese Academy of Medical Sciences
IRCCS Istituto Giannina Gaslini - Ospedale Pediatrico
Mahidol University
Universität Ulm
Hospital Universitario Donostia
The Catholic University of Korea
Nagoya University
Fondazione Policlinico Universitario Agostino Gemelli IRCCS Università Cattolica del Sacro Cuore
Chinese Academy of Medical Sciences
IRCCS Istituto Giannina Gaslini - Ospedale Pediatrico
Mahidol University
Universität Ulm
Hospital Universitario Donostia
The Catholic University of Korea
Nagoya University
Abstract
© 2018 Wiley Periodicals, Inc. The aim of this study was to assess the outcome of patients with aplastic anemia (AA), receiving rabbit anti-thymocyte globulin (Thymoglobulin, SANOFI) and cyclosporin, as first line treatment. Eligible were 955 patients with AA, treated first line with Thymoglobulin, between 2001 and 2008 (n = 492), or between 2009 and 2012 (n = 463). The median age of the patients was 21 years (range 1-84). Mortality within 90 days was 5.7% and 2.4%, respectively in the two time periods (P =.007).The actuarial 10-year survival for the entire population was 70%; transplant free survival was 64%. Predictors of survival in multivariate analysis, were severity of the disease, patients age and the interval between diagnosis and treatment. Survival was 87% vs 61% for responders at 6 months versus nonresponders (P <.0001). The 10-year survival of nonresponders at 6 months, undergoing a subsequent transplant (n = 110), was 64%, vs 60% for patient not transplantated (n = 266) (P =.1). The cumulative incidence of response was 37%, 52%, 65% respectively, at 90, 180, and 365 days. In multivariate analysis, negative predictors of response at 6 months, were older age, longer interval diagnosis treatment, and greater severity of the disease. In conclusion, early mortality is low after first line treatment of AA with Thymoglobulin, and has been further reduced after year 2008. Patients age, together with interval diagnosis—treament and severity of the disease, remain strong predictors of response and survival.